Takeda’s Zasocitinib: A Once-Daily Pill That Could Redefine Psoriasis Treatment

For years, the gold standard in psoriasis has been clear: injectables deliver the best results. Now, Takeda Pharmaceutical Company is challenging that assumption with a pill.

At the American Academy of Dermatology Annual Meeting, Takeda unveiled Phase 3 data showing that zasocitinib (TAK-279), an oral TYK2 inhibitor, can deliver rapid, durable skin clearance in moderate-to-severe plaque psoriasis.

Why This Matters: Breaking the Injectable Barrier?

Psoriasis treatment has a trade-off:

• Injectables (biologics): high efficacy
• Oral drugs: convenience, but weaker outcomes

Zasocitinib aims to combine both:

• Biologic-level efficacy
• Pill-level convenience

If validated, that’s a category shift.

The Data: Strong Efficacy Across Key Endpoints

The results come from two large Phase 3 trials:

• Latitude PsO 3001
• Latitude PsO 3002

At Week 16:

Clear or Almost Clear Skin (sPGA 0/1):

• ~71% and 69% (zasocitinib)
• vs ~11–13% (placebo)
• vs ~30% (apremilast)

High-Level Skin Clearance (PASI 90):

• 61% and 52% (zasocitinib)
• vs ~4–5% (placebo)
• vs ~16% (apremilast)

Complete Clearance (The New Benchmark)

• sPGA 0 (fully clear skin) → up to ~40%
• PASI 100 (complete clearance) → up to ~33%

These are clinically meaningful numbers, especially for an oral therapy.

Speed and Durability: Two Critical Wins

Fast onset:

• Response seen as early as Week 4

Long-lasting results:

• >90% of responders maintained outcomes at Week 60

Translation: It works fast—and keeps working.

Safety Profile: Consistent, No Surprises

Zasocitinib was generally well tolerated.

Key observations:

• Common side effects:
  • Upper respiratory infections (~10%)
  • Nasopharyngitis (~6%)
  • Acne (~6%)
• No new safety signals
• Serious adverse events: ~3%

Importantly, safety remained consistent with earlier Phase 2b data.

The Science: Why TYK2 Selectivity Matters?

Zasocitinib targets TYK2, part of the JAK family—but with a twist.

What makes it different:

• 1,000,000+ times more selective for TYK2 vs JAK1/2/3
• Targets IL-23 and key inflammatory pathways
• Avoids broader JAK-related safety risks

Translation: Precision targeting → efficacy without the baggage.

Competitive Positioning

Zasocitinib isn’t entering an empty market.

Key competitor:

• Deucravacitinib (another TYK2 inhibitor)

Takeda is already:

• Running head-to-head trials
• Expanding into:
  • Psoriatic arthritis
  • Crohn’s disease
  • Ulcerative colitis
  • Vitiligo
  • Hidradenitis suppurativa

This is shaping up to be a platform drug, not just a psoriasis therapy.

What Happens Next?

Takeda plans to:

• File a New Drug Application (NDA) with the U.S. Food and Drug Administration
• Begin submissions in FY 2026

Important: Zasocitinib is not yet approved anywhere globally.

The Bigger Picture: A Shift in Treatment Paradigm

Psoriasis affects:

• ~64 million people globally
• 80–90% with plaque psoriasis

It’s not just a skin condition:

• Chronic inflammation
• Mental health burden
• Quality-of-life impact

A once-daily pill delivering near-biologic outcomes could:

• Improve adherence
• Expand access
• Reduce reliance on injections

Final Take

Zasocitinib hits a rare combination:

• High efficacy (approaching biologics)
• Oral convenience
• Targeted safety profile

If regulatory approvals follow, this could become: The first oral therapy to seriously challenge biologics in psoriasis. And that’s a big deal.